New developments in aminoglycoside therapy and ototoxicity

Area of Science:

• Pharmacology and Toxicology
• Oto-neuroscience
• Antimicrobial Drug Development

Background:

• Aminoglycoside antibiotics have been clinically used for nearly 70 years.
• They remain essential for treating acute infections, tuberculosis, and Pseudomonas aeruginosa in cystic fibrosis patients.
• Aminoglycoside toxicity, particularly ototoxicity and vestibular toxicity, is a significant clinical concern.

Purpose of the Study:

• To review the pathology and pathophysiology of aminoglycoside-induced auditory and vestibular toxicity.
• To explore current understanding of the mechanisms underlying aminoglycoside-induced cell death.
• To outline current protective therapies and advancements in developing less toxic aminoglycoside derivatives.

Main Methods:

• Literature review of existing studies on aminoglycoside toxicity.
• Analysis of pathological and pathophysiological data from human and animal models.
• Synthesis of contemporary research on cell death mechanisms and therapeutic strategies.

Main Results:

• Aminoglycosides induce auditory and vestibular toxicity through specific cellular mechanisms.
• Current protective therapies offer partial mitigation of toxicity.
• New aminoglycoside derivatives show promise for reduced toxicity and novel applications.

Conclusions:

• Understanding aminoglycoside toxicity mechanisms is crucial for clinical management.
• Development of low-toxicity aminoglycosides is advancing for antimicrobial and genetic disorder treatments.
• Continued research is needed to optimize aminoglycoside therapy and minimize adverse effects.